A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary arterial hypertension (PAH). “This study combined [computer-based genetic sequencing] analyses with experimental validation [in cell and animal models] to identify COL1A1, MYL9, COL1A2, and TPM2 as potential key driver genes…
Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in a rat model of PAH. The scientists detailed the development and testing of the treatment, CPD1, in a study that also shed light on the molecular mechanisms through which the…
Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical role of clinical research. Led by PHA Europe, the annual event seeks to raise awareness and improve the lives of those living with pulmonary hypertension (PH), a condition…
Corvista Health will collaborate with Mayo Clinic to evaluate whether its non-invasive Corvista-PH test can improve the detection, risk stratification, and referral accuracy for people with suspected pulmonary hypertension (PH). “Collaborating with Mayo Clinic represents a defining moment for CorVista and for the advancement of pulmonary hypertension diagnostics,”…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
